Therapeutic Advances in Ophthalmology最新文献

{"title":"Combined phacovitrectomy for retinal detachment and cataract-macular attachment and visual fixation as predictors of postoperative refractive error.","authors":"Anna Hillenmayer, Christian M Wertheimer, Susanna F Koenig, Lennart M Hartmann, Tim Freisenich, Dorian Begaj, Armin Wolf, Efstathios Vounotrypidis","doi":"10.1177/25158414251378632","DOIUrl":"10.1177/25158414251378632","url":null,"abstract":"<p><strong>Background/objectives: </strong>To evaluate the effect of macular status and fixation, as determined by chord alpha, on refractive outcomes following combined phacovitrectomy for retinal detachment. Although an optical biometer can be used to calculate the required dioptric power of the intraocular lens, loss of central fixation can introduce errors into the biometric parameters.</p><p><strong>Design: </strong>Retrospective single-center observational study.</p><p><strong>Methods: </strong>Patients with retinal detachment and cataract who underwent combined phacoemulsification and vitrectomy following swept-source optical coherence tomography-based biometry (ZEISS IOLMaster 700) were included, and their preoperative macular status, chord-alpha length, and resulting refractive error at the final follow-up appointment were recorded.</p><p><strong>Results: </strong>A total of 305 eyes were evaluated, of which 150 had macular detachment. There was a statistically significantly higher rate of refractive error in eyes with macular detachment compared to eyes without (<i>p</i> < 0.001). Absolute refractive prediction error of more than 1 diopter was found in 31% of eyes with detached maculae, compared to 12% of eyes without macular involvement. Eyes with a detached macula showed a significantly longer chord alpha (right eye: <i>p</i> = 0.01; left eye: <i>p</i> < 0.0001), and linear regression analysis revealed that a longer chord alpha was associated with a myopic refractive error. The presence of other factors that also correlated with refractive error underscores the multifactorial pathogenesis of refractive prediction error.</p><p><strong>Conclusions: </strong>Compared to non-macular involvement, macular detachment led to worse refractive outcomes in combined phacovitrectomy, and chord alpha, as a marker for central fixation, might serve as an explanation. Further research is needed to determine whether combined phacoemulsification and vitrectomy should be performed in patients with macular detachment.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251378632"},"PeriodicalIF":2.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations in tear film and wavefront parameters associated with different types of disposable surgical masks in healthcare personnel during working hours: a randomized trial.","authors":"Somporn Chantra, Nalinrat Disayavatin, Parinee Kemchoknatee","doi":"10.1177/25158414251378120","DOIUrl":"10.1177/25158414251378120","url":null,"abstract":"<p><strong>Background: </strong>Facial masks are essential for preventing respiratory infections, particularly among healthcare workers. However, prolonged mask use may lead to ocular surface disruption, known as mask-associated dry eye (MADE).</p><p><strong>Objectives: </strong>To evaluate the impact of different types of disposable surgical masks on tear film parameters and corneal wavefront aberrations during an 8-h work shift.</p><p><strong>Design: </strong>Randomized clinical trial.</p><p><strong>Methods: </strong>Sixty healthcare personnel at Rajavithi Hospital were randomly assigned to three mask groups: Group 1 (earloop surgical mask; Medimask^®), Group 2 (earloop surgical mask with adhesive nose strip), and Group 3 (anti-fog earloop surgical mask; Welcare 3D Blue Line Anti-Fog Mask^®). Non-invasive tear breakup time (NIBUT), tear meniscus height (TMH), and conjunctival redness were assessed using the Oculus Keratograph^®5M. Corneal higher-order aberrations (HOAs) were measured using the GALILEI Dual Scheimpflug Analyzer before and after 8 h of mask wear.</p><p><strong>Results: </strong>TMH decreased significantly in all groups: Group 1 from 201.13 ± 85.10 µm to 174.53 ± 42.01 µm (<i>p</i> = 0.003), Group 2 from 188.81 ± 59.55 µm to 164.61 ± 50.58 µm (<i>p</i> = 0.036), and Group 3 from 194.50 ± 58.29 µm to 166.25 ± 45.90 µm (<i>p</i> = 0.034). NIBUT showed slight, non-significant decreases: Group 1 (9.26 ± 4.47-8.35 ± 3.26 s), Group 2 (8.88 ± 3.79-8.20 ± 3.12 s), and Group 3 (9.14 ± 4.20-8.55 ± 3.74 s). Conjunctival redness increased significantly only in Group 1 (1.75 ± 0.47-1.98 ± 0.52, <i>p</i> = 0.048). HOAs were mostly unchanged, except for total HOAs at the 6 mm zone, which were higher in Group 3 (1.85 ± 1.20) than in Group 1 (1.14 ± 0.48) and Group 2 (1.28 ± 0.58; <i>p</i> = 0.012).</p><p><strong>Conclusion: </strong>An 8-h shift of mask use reduced TMH across all groups and increased conjunctival redness in earloop surgical masks without adhesive. Although most optical aberrations remained unchanged, elevated HOAs in the anti-fog earloop surgical mask group may affect vision quality under mesopic conditions.</p><p><strong>Thai clinical trials registry: </strong>TCTR 20230725002 (https://www.thaiclinicaltrials.org/show/TCTR20230725002).</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251378120"},"PeriodicalIF":2.3,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrastromal corneal ring segments for keratoconus: a comprehensive review of different types.","authors":"Yehya Tlaiss, John Warrak, Elias Warrak","doi":"10.1177/25158414251371521","DOIUrl":"10.1177/25158414251371521","url":null,"abstract":"<p><p>This comprehensive review analyzes different types of intrastromal corneal ring segments (ICRS) used in the treatment of keratoconus, focusing on visual outcomes, complication rates, and patient selection criteria for INTACS, KeraRing, Ferrara Ring, MyoRing, and corneal allogenic intrastromal ring segments (CAIRS). We reviewed clinical studies, case reports, and long-term follow-ups to compare visual outcomes, corneal stability, and safety profiles of these ICRS types, with specific emphasis on parameters such as uncorrected distance visual acuity (UDVA), best-corrected distance visual acuity (CDVA), keratometry (Kmax reduction), and complication rates, including migration, extrusion, and postoperative visual disturbances. Each type of ICRS exhibits distinct advantages, with efficacy varying according to disease severity and corneal irregularity. INTACS demonstrated reliable visual improvements for moderate keratoconus with minimal complication rates. KeraRing provided customizable options that significantly improved UDVA and CDVA in cases with irregular astigmatism, although segment migration was more common. The Ferrara Ring was highly effective in central keratoconus, offering substantial corneal flattening with a moderate risk of visual disturbances. MyoRing effectively reduced higher-order aberrations in advanced keratoconus but was associated with a higher reoperation rate. CAIRS, combined with corneal crosslinking, showed promising outcomes with enhanced biocompatibility and minimal complications, particularly for patients sensitive to synthetic materials. ICRS types offer tailored options for keratoconus management. INTACS remains effective for moderate cases, while KeraRing and Ferrara Ring are suitable for advanced stages, especially where customization and flattening are needed. MyoRing offers significant benefits for severe ectasia, and CAIRS presents a novel, biocompatible alternative. Optimizing outcomes and minimizing complications requires tailored selection based on patient-specific corneal characteristics and disease stage. Further comparative studies are needed to refine patient selection criteria and assess the long-term efficacy of each ICRS type.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251371521"},"PeriodicalIF":2.3,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical erythropoietin in the management of scleral necrosis: a narrative review.","authors":"Kosar Namakin, Sara Ziayifard, Zahra Tahmasbi, Atefeh Jafarian, Sepehr Feizi","doi":"10.1177/25158414251365749","DOIUrl":"10.1177/25158414251365749","url":null,"abstract":"<p><p>Scleral necrosis is a rare but severe complication caused by various etiologies. The main therapeutic approach is topical and systemic medical treatment. Surgical interventions may be indicated in unresponsive cases. These approaches, however, may fail to control the scleral necrosis. In addition, both medical and surgical treatment may lead to a number of ocular and systemic side effects, calling for noninvasive but effective treatment for the management of scleral necrosis. This review aims to summarize current studies investigating the role of topical erythropoietin in the treatment of scleral necrosis caused by various etiologies. Different electronic databases were extensively searched for relevant studies published until May 30, 2025, using the following keywords: \"erythropoietin\" AND \"scleral necrosis\" OR \"necrotizing scleritis\" OR \"scleral ischemia.\" The primary outcomes assessed were the indication for topical erythropoietin administration, with secondary outcomes including the efficacy and ocular and systemic safety of treatment with this medication. Seven studies reported the outcomes of the administration of topical erythropoietin for the treatment of scleral necrosis. Of which, two were experimental studies, two were single case reports, including three eyes of two patients, two were case series, including 11 eyes of 11 patients, and one was a nonrandomized case-control study, including 11 eyes of nine patients. Etiologies for scleral necrosis were chemical burns in 15 eyes, thermal burn in one eye, surgically-induced scleral necrosis in six eyes, and systemic autoimmune diseases in three eyes. The necrotic lesions were improved in all eyes 9-90 days after the initiation of treatment with topical erythropoietin. Regarding ocular safety, two eyes developed granulation tissue, which resolved after the cessation of the treatment. Corneal vascularization was observed in 16 eyes with limbal stem cell deficiency due to chemical/thermal burns. No intraocular vascularization or systemic adverse reactions were observed during treatment with topical erythropoietin. Topical administration of erythropoietin can be safe and effective for the management of scleral necrosis caused by various etiologies. However, more studies, including randomized clinical trials, are needed to establish the role of topical erythropoietin in the treatment of this rare but sight-threatening complication.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251365749"},"PeriodicalIF":2.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10-Year outcome of descemet stripping only in a patient with Fuchs endothelial dystrophy: a case report.","authors":"Fuad Moayed, Friedrich Anton Steindor, Zaira Eleni Armeni, Markus Kohlhaas, Gerd Geerling","doi":"10.1177/25158414251359583","DOIUrl":"10.1177/25158414251359583","url":null,"abstract":"<p><p>In recent years, descemet stripping only (DSO) has emerged as an alternative to descemet membrane endothelial keratoplasty (DMEK) in certain patients with Fuchs endothelial dystrophy (FED). We herein report the 10-year follow-up of a 77-year-old male patient after bilateral DSO. The patient initially underwent DSO on the right eye for circumscribed cornea guttata. Three weeks after DSO, the best-corrected visual acuity (BCVA) already increased from 0.5 logarithm of the Minimum Angle of Resolution (logMAR) [Endothelial Cell Density (ECD) 1667/mm², Central Corneal Thickness (CCT) 583 µm] to 0.2 logMAR, and further improved to 0 logMAR 1 year after surgery (ECD 2213/mm², CCT 567 µm). This excellent visual acuity remained stable over the following 5 years (ECD 1696/mm², CCT 568 µm). Five years after the successful surgery on the right eye, DSO was also performed on the left eye by the same surgeon as FED progressed, with BCVA dropping to 0.5 logMAR (ECD unmeasurable, CCT 703 µm). However, this time, the treatment did not improve vision. Consequently, a DMEK was performed 7 months after DSO, which increased the BCVA to 0.1 logMAR. Ten years after successful DSO of the right eye, corneal guttata were observed, indicating de novo formation of a descemet membrane, and vision deteriorated again to 0.2 logMAR (ECD not measurable, CCT 641 µm). DMEK was also performed on the right eye ten years after successful DSO, which improved vision to 0.2 logMAR at one-year follow-up. This case suggests that DSO may be a temporary alternative to DMEK in FED, potentially providing excellent visual gain and good central endothelial cell density for nearly ten years. However, it may still fail due to long-term progression of the disease. It also highlights that the outcome may be limited by individual factors. Therefore, it is crucial to educate the patient about the limitations of DSO, both in short and long term. Nevertheless, if DSO fails, endothelial keratoplasty can still be successfully performed.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251359583"},"PeriodicalIF":2.3,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Charles Bonnet Syndrome Special Collection.","authors":"Judith Potts","doi":"10.1177/25158414251362980","DOIUrl":"10.1177/25158414251362980","url":null,"abstract":"","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251362980"},"PeriodicalIF":2.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of pain scores during intravitreal injection in systemic conditions and in conjunction with medications.","authors":"Taha Sezer, Emir Altıkardeşler, Kübra Erdoğan, Betül Arslan, Kübra Çolak","doi":"10.1177/25158414241275360","DOIUrl":"10.1177/25158414241275360","url":null,"abstract":"<p><strong>Background: </strong>Intravitreal injection (IVI) is a common practice in today's ophthalmology clinics. The pain that patients will experience after the application may be important in compliance with the treatment.</p><p><strong>Objectives: </strong>This study aimed to investigate the correlation between various clinical characteristics of patients receiving IVI and corresponding visual analogue scale (VAS) scores (0: no pain to 10: severe pain).</p><p><strong>Design: </strong>Single-centre, Prospective study.</p><p><strong>Methods: </strong>A total of 313 participants (168 females, 145 males) with a mean age of 66.91 ± 9.67 years underwent IVI for diabetic retinopathy (DRP), retinal vein occlusion (RVO), or age-related macular degeneration (AMD). Eye examinations, including visual acuity and intraocular pressure measurements, were also conducted, and injection indications were determined based on dilated fundus examinations and spectral domain optical coherence tomography images. Following the injections, the researchers solicited VAS scores ranging from 0 to 10 (no pain to severe pain). The study explored the relationships between clinical characteristics, headache frequency, joint and muscle pain, analgesic use, surgical history, antidepressant use, vasovagal syncope, previous injections, and VAS score.</p><p><strong>Results: </strong>The mean VAS score was 4.77 ± 2.90. While DRP and RVO had similar VAS scores (4.95 ± 2.98 and 5.22 ± 2.70, respectively), the AMD group had significantly lower scores (4.09 ± 2.64). Compared with nonusers, antidepressant users had significantly greater VAS scores (5.79 ± 3.43) (4.52 ± 2.70) (<i>p</i> < 0.05). Patients with a history of syncope had significantly greater VAS scores (<i>p</i> < 0.05). In patients reporting monthly headaches, a positive correlation was found between headache frequency and VAS score (<i>r</i> = 0.23, <i>p</i> < 0.01).</p><p><strong>Conclusion: </strong>For individuals experiencing daily headaches, inquiries about vasovagal syncope and antidepressant use may be beneficial, considering the potential association of these symptoms with higher VAS scores after IVIs.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414241275360"},"PeriodicalIF":2.3,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.","authors":"Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, Sergio Leal, Frank G Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y Wong","doi":"10.1177/25158414251356388","DOIUrl":"10.1177/25158414251356388","url":null,"abstract":"&lt;p&gt;&lt;p&gt;What is this summary about? • This is a summary of a publication about the PULSAR study, which was published in &lt;i&gt;The Lancet&lt;/i&gt; scientific journal. • Wet age-related &lt;b&gt;macular degeneration&lt;/b&gt; (or AMD) is a long-term eye disease in which abnormal blood vessels grow in the back of the eye. As these vessels leak fluid or blood, the word \"wet\" is part of the disease name. This affects the central part of a person's vision, which can make it hard for people to read, drive, or perform other daily activities. It is one of the main causes of visual loss in older people, and if it is left untreated, it can lead to rapid loss of vision. • People with wet AMD can be treated with anti-vascular endothelial growth factor (or anti-&lt;b&gt;VEGF&lt;/b&gt;) medicine, given as an injection into the back of the eye. This type of medicine can improve vision by directly reducing the leakage into the &lt;b&gt;macula&lt;/b&gt; and by stopping the growth of new, abnormal blood vessels. This leads to reduced swelling of the &lt;b&gt;macula&lt;/b&gt;, which is measured by central retinal thickness. These therapies need frequent eye injections. One of the biggest difficulties for many people and their caregivers is that they need to keep up with visits for their injections that are often required to maintain good vision. • &lt;b&gt;Aflibercept&lt;/b&gt; is an anti-&lt;b&gt;VEGF&lt;/b&gt; medicine that health authorities across different countries have approved for the treatment of wet AMD, as well as other eye diseases, which we will not discuss in this material. People with wet AMD can receive injections of &lt;b&gt;aflibercept&lt;/b&gt; 2 mg, given initially once per month for three months. After that, people usually receive treatment every 8 weeks, or sometimes less frequently, depending on their doctors' assessments of the disease state. • The PULSAR study was carried out to see if a higher, 8 mg, dose of &lt;b&gt;aflibercept&lt;/b&gt; would provide the same treatment results as &lt;b&gt;aflibercept&lt;/b&gt; 2 mg, but with the need for fewer injections. If fewer injections are necessary, this can potentially help patients and their caregivers keep up with treatment. • The PULSAR study involved a direct comparison of the two doses of this anti-VEGF medicine in patients with wet AMD who were placed into one of three treatment groups with different dosing intervals at random. What were the results? • Through the first year (or 48 weeks), participants who received injections of &lt;b&gt;aflibercept&lt;/b&gt; 8 mg every 12 or 16 weeks after an injection once per month for three months, had improvements in vision that were similar to those of participants treated with &lt;b&gt;aflibercept&lt;/b&gt; 2 mg every 8 weeks. • After the injection once per month for three months, at Week 16, there were fewer participants treated with the 8 mg dose who had abnormal fluid leakage in the &lt;b&gt;macula&lt;/b&gt; compared to the 2 mg dose. • At Week 48, participants who received &lt;b&gt;aflibercept&lt;/b&gt; 8 mg had similar decreases in the thickness of the retina in the central region as those treated with &lt;b&gt;afl","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251356388"},"PeriodicalIF":2.3,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12361716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descemet's membrane endothelial keratoplasty in an eye with iridocorneal endothelial syndrome and rare association of corneal ectasia.","authors":"Mohammad Saleki, Preston Lee, Caroline Thaung, Zahra Ashena","doi":"10.1177/25158414251343968","DOIUrl":"10.1177/25158414251343968","url":null,"abstract":"<p><p>We report the first case of concurrent iridocorneal endothelial (ICE) syndrome and keratoconus, treated successfully with Descemet's membrane endothelial keratoplasty (DMEK). A 60-year-old male presented with gradual visual deterioration in his left eye over 4 years. Best corrected visual acuity was 1.1 LogMar, with corneal stromal oedema. Hypertonic saline and systemic acyclovir provided no improvement. Further examination revealed peripheral anterior synechiae and possible ICE syndrome. Combined cataract surgery and adapted DMEK were performed, using right eye data for intraocular lens calculation. Postoperative histopathology confirmed ICE syndrome. Two months postoperatively, vision improved to 0.54 LogMar, with normal intraocular pressure and optical coherence tomography. Ten months later, unaided visual acuity reached 0.4 LogMar, with no significant changes observed in regular follow-ups. The patient remains satisfied with his vision. This case highlights the rare association of keratoconus with Chandler Syndrome and the first report of such a case where DMEK was used as management. The diagnosis of ICE syndrome complicates treatment, however, despite the challenges, DMEK demonstrated promising results for ICE-related corneal oedema in a patient with concurrent keratoconus, offering improved visual acuity and no complications.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251343968"},"PeriodicalIF":2.3,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12361739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical spectrum and management of anterior scleritis: case reports.","authors":"Dominika Ördögh, Lilla Smeller, Dóra Júlia Szabó, Nicolette Sohár","doi":"10.1177/25158414251356374","DOIUrl":"10.1177/25158414251356374","url":null,"abstract":"<p><p>Scleritis is a rare, potentially sight-threatening, painful eye disease. Based on its anatomical involvement, it can be categorized as anterior and posterior scleritis. There are several possible causes, among which infectious and noninfectious origins should be considered. From the therapeutic aspect, it is important to clarify the infectious origin, to provide target treatment, or to identify the possible underlying autoimmune disease. Corticosteroid therapy is considered to be the basis for the stepwise treatment of scleritis. In this article, we describe the management of three patients (investigations, stepwise approach of therapy, and treatment difficulties) who developed three different types of scleritis: anterior non-necrotizing scleritis, anterior necrotizing scleritis, and scleromalacia perforans. The differential diagnosis of scleritis and its management after diagnosis pose difficulties in clinical practice. In general, the therapeutic approach is based on the principle of early and individualized treatment, which depends on the nature and severity of the patient's inflammatory eye disease and the presence or absence of associated systemic diseases.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251356374"},"PeriodicalIF":2.3,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}